scorecardresearchSun Pharmaceutical Industries Share Price Live NSE, BSE, Today - Sun Pharmaceutical
Mintgenie
Asian Paints3,276.0533.70 (1.04%)
Axis Bank1,018.203.25 (0.32%)
Bajaj Finance7,468.00-11.15 (-0.15%)
Bajaj Finserve1,542.3017.00 (1.11%)
Bharti Airtel912.60-5.50 (-0.60%)
HCL Technologies1,273.50-5.00 (-0.39%)
HDFC Bank1,529.20-24.40 (-1.57%)
Hindustan Unilever2,482.307.60 (0.31%)
ICICI Bank950.30-9.05 (-0.94%)
ITC443.20-4.20 (-0.94%)
Indusind Bank1,452.7541.20 (2.92%)
Infosys1,496.00-5.85 (-0.39%)
Kotak Mahindra Bank1,756.550.20 (0.01%)
Larsen & Toubro2,918.8519.10 (0.66%)
Mahindra & Mahindra1,607.8024.00 (1.52%)
Maruti Suzuki India10,536.45240.45 (2.34%)
NTPC237.95-1.00 (-0.42%)
Nestle India22,574.9548.90 (0.22%)
Power Grid Corporation Of India199.10-2.70 (-1.34%)
Reliance Industries2,354.05-10.50 (-0.44%)
State Bank Of India598.109.80 (1.67%)
Sun Pharmaceutical Industries1,131.60-14.40 (-1.26%)
Tata Consultancy Services3,602.6518.70 (0.52%)
Tata Motors621.10-5.80 (-0.93%)
Tata Steel126.70-1.10 (-0.86%)
Tech Mahindra1,305.0012.15 (0.94%)
Titan Company3,273.10-29.35 (-0.89%)
Ultratech Cement8,181.10-124.95 (-1.50%)
Wipro418.65-9.95 (-2.32%)

Sun Pharmaceutical Industries

BSE: 524715 | NSE: SUNPHARMA | ISIN: INE044A01036 | SECTOR: Biotechnology & Drugs

₹1,131.60 -14.40 (-1.26%)

22 Sep 2023, 10:18 (IST)

  • Open

    1,140.05

  • High

    1,145.45

  • Low

    1,128.75

  • Prev Close

    1,146.00

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    2,715.09B

  • Volume

    36.49K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    -
View all metrics

Promoter Pledge Holding - 1.25%

Promoter NameNo of SharesPercentage
Kumud Shantilal Shanghvi1,00,0000.00%
Aditya Medisales Limited51,40,0000.21%
Raksha Valia2,46,70,0001.02%

Company Description

  • Biotechnology & Drugs

  • BSE

    524715

  • NSE

    SUNPHARMA

  • ISIN

    INE044A01036

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). It produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The Company's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The Company also has a product portfolio in RoW markets, including injectables, hospital products and retail products. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.

Company Officers

  • C. S. Muralidharan

    Chief Financial Officer

  • Uday Baldota

    Chief Executive Officer - Taro Pharmaceutical Industries Limited

  • S. Damodharan

    Chief Executive Officer - API Business

  • Abhay Gandhi

    Chief Executive Officer - North America

  • Kirti Ganorkar

    Chief Executive Officer - India Business

  • Aalok Shanghvi

    Whole-time Director, Executive Vice-President, Emerging Markets, Global generic R&D, Global BD (Generics Segment) & API

  • Jila Breeze

    Executive Vice President, Global Head - Quality

  • Anil Rao

    Senior Vice President, Chief Information Officer

  • Sapna Purohit

    Senior Vice President, Head of Human Resources

  • Azadar Khan

    Senior Vice-President, Corporate Relations and Corporate Social Responsibility